MedTrace Logo

Phase1, Single Dose, Crossover Study to Determine Bioequivalence

NCT00786240 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2010-09-09

No results posted yet for this study

Summary

The objective of this study is to demonstrate bioequivalence of 4 mg tablet of formulation D and formulation E(1).

Conditions

  • Healthy

Interventions

DRUG

Fesoterodine

Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)

DRUG

Fesoterodine

Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00786240 on ClinicalTrials.gov